

Notice of Allowability	Application No.	Applicant(s)
	09/616,223	NADEL ET AL.
	Examiner Jane Zara	Art Unit 1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 2-4-04.
2. The allowed claim(s) is/are 1 and 12-16.
3. The drawings filed on 14 July 2000 are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some* c) None
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 10-28-03
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

Examiner's Amendment

The following has been inserted on page 1 of the specification, before
"GOVERNMENT RIGHTS":

--This application is a CIP of 09/375597, now USPN 6,270,747, filed 8-17-99,
which claims benefit of 60/097,023, filed 8-18-98.--

Reasons for Allowance

The following is an examiner's statement of reasons for allowance: The claimed invention is free of the prior art of record because the prior art of record does not teach or fairly suggest a method of reducing goblet cell hyperplasia in an airway of an individual suffering from mucus hypersecretion comprising the administration of an EGF-R antagonist that binds the EGF-R in an amount effective to reduce goblet cell hyperplasia.

Examiner's Comments

Applicants have demonstrated the relationship between the inhibition of EGF-R activation, a reduction in goblet cell hyperplasia, an inhibition of mucin expression and production, and the subsequent inhibition of airway mucus hypersecretion *in vivo*. EGF-R activation was accomplished using various agents, including EGF ligands, TNF-alpha, cigarette smoke, ovalbumin sensitization, intratracheal instillation of agarose plugs, activated neutrophils and IL-13. Inhibition of EGF-R activation and the subsequent

reduction in goblet cell hyperplasia, mucin production and airway mucus hypersecretion was demonstrated using Tyrphostin Ag 1478, cyclophosphamide, TNF-alpha neutralizing antibodies, NPC 15669, anti-EGF-R antibodies and BIBX1522. These EGF-R antagonists were administered systemically (IP, IV), by intratracheal instillation, and in aerosolized form (lung delivery).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Certain papers related to this application may be submitted to Art Unit 1635 by facsimile transmission. The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). The official fax telephone number for the Group is **703-872-9306**. NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by applicant or applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers in the Office.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jane Zara** whose telephone number is **(571) 272-0765**. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, John LeGuyader, can be reached on (571) 272-0760. Any inquiry regarding this application should be directed to the patent analyst, Katrina Turner, whose telephone number is (571) 272-0564. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.



RAM R. SHUKLA, PH.D.
PRIMARY EXAMINER

JZ
February 4, 2004